Cagrilintide-semaglutide (CagriSema) combination investigated for enhanced glycemic control and weight loss in type 2 diabetes.

Managing type 2 diabetes (T2D) and associated overweight/obesity often requires multi-faceted approaches, as current monotherapies may not achieve optimal glycemic control and weight reduction. GLP-1 receptor agonists like semaglutide are highly effective, but combining mechanisms can offer synergistic benefits. Amylin receptor agonists, such as cagrilintide, complement GLP-1 agonism by enhancing satiety and further improving glycemic outcomes. This study explores the potential of CagriSema, a novel combination, to address these gaps by leveraging both GLP-1R and amylin receptor pathways.

REIMAGINE 2 was a 68-week, double-blind, randomized, placebo- and active-controlled, parallel-group phase 3 study across 30 countries. Participants (aged 18+ years) with inadequately controlled type 2 diabetes (HbA1c 7.0-10.5%) on metformin (with/without SGLT2i) and a BMI of ≥25 kg/m² were randomized to once-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg (CagriSema), semaglutide 2.4 mg, cagrilintide 2.4 mg, cagrilintide 1.0 mg plus semaglutide 1.0 mg, semaglutide 1.0 mg, or corresponding placebo. Randomization used a web-based system with blocked allocation. The primary endpoint was change in HbA1c from baseline to week 68 for CagriSema (2.4 mg each) versus semaglutide 2.4 mg.

The abstract provided did not include the study findings. Therefore, specific efficacy and safety outcomes, including changes in HbA1c, body weight, or adverse event rates, cannot be reported from this abstract. The study design indicates a comprehensive investigation into the comparative effects of CagriSema against its individual components and placebo over 68 weeks.